Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
复制标题
DOI：
10.1007/s10549-015-3436-x
复制
发表时间：
2015-07
影响因子：
3.8
通讯作者：
Ueno, Naoto T.
中科院分区：
文献类型：
--
作者：
Fouad, Tamer M.;Kogawa, Takahiro;Liu, Diane D.;Shen, Yu;Masuda, Hiroko;El-Zein, Randa;Woodward, Wendy A.;Chavez-MacGregor, Mariana;Alvarez, Ricardo H.;Arun, Banu;Lucci, Anthony;Krishnamurthy, Savitri;Babiera, Gildy;Buchholz, Thomas A.;Valero, Vicente;Ueno, Naoto T.
炎性乳腺癌（IBC）是一种罕见的侵袭性疾病。先前的研究表明，在 III 期乳腺癌患者中，IBC 的预后比非炎症性乳腺癌 (non-IBC) 更差。尚未研究这种差异在 IV 期乳腺癌患者中是否成立。我们检验了以下假设：在诊断时发生远处转移（IV 期疾病）的 IBC 患者中，IBC 患者的总生存期 (OS) 比非 IBC 患者的总生存期 (OS) 更差。我们回顾了 1987 年至 2012 年在我们机构接受治疗的 1504 名连续 IV 期乳腺癌患者（IBC：206；非 IBC：1298）的记录。比较了 IBC 和非 IBC 亚组的生存曲线。 Cox 比例风险模型用于确定 OS 的预测因子。中位随访时间为 4.7 年。 IBC 与非 IBC 相比，中位 OS 时间较短（2.27 年 vs. 3.40 年；P = 0.0128，对数秩检验）。在包含 1389 名患者的多协变量 Cox 模型中，IBC 的诊断是 OS 较差的重要独立预测因子（风险比 = 1.431，P = 0.0011）。较差 OS 的其他重要预测因素包括黑人（相对于白人）种族、诊断时的年龄较小、HER2 阴性状态以及内脏（相对于非内脏）转移部位。在诊断时发生远处转移的患者中，IBC 的 OS 比非 IBC 的患者要短。 IV 期乳腺癌患者应考虑 IBC 的预后影响。
Inflammatory breast cancer (IBC) is a rare and aggressive disease. Previous studies have shown that among patients with stage III breast cancer, IBC is associated with a worse prognosis than noninflammatory breast cancer (non-IBC). Whether this difference holds true among patients with stage IV breast cancer has not been studied. We tested the hypothesis that overall survival (OS) is worse in patients with IBC than in those with non-IBC among patients with distant metastasis at diagnosis (stage IV disease). We reviewed the records of 1504 consecutive patients with stage IV breast cancer (IBC: 206; non-IBC: 1298) treated at our institution from 1987 through 2012. Survival curves for IBC and non-IBC subcohorts were compared. The Cox proportional hazards model was used to determine predictors of OS. The median follow-up period was 4.7 years. IBC was associated with shorter median OS time than non-IBC (2.27 years vs. 3.40 years; P = 0.0128, log-rank test). In a multicovariate Cox model that included 1389 patients, the diagnosis of IBC was a significant independent predictor of worse OS (hazard ratio = 1.431, P = 0.0011). Other significant predictors of worse OS included Black (vs. White) ethnicity, younger age at diagnosis, negative HER2 status, and visceral (vs. nonvisceral) site of metastasis. IBC is associated with shorter OS than non-IBC in patients with distant metastasis at diagnosis. The prognostic impact of IBC should be taken into consideration among patients with stage IV breast cancer.
登录
查看更多内容
影响因子：
3.7
作者：
Curcio, LD;Rupp, E;Wagman, LD
通讯作者：
Wagman, LD
影响因子：
10.3
作者：
Hance, KW;Anderson, WF;Levine, PH
通讯作者：
Levine, PH
影响因子：
45.3
作者：
Andre, F;Slimane, K;Spielmann, M
通讯作者：
Spielmann, M
影响因子：
45.3
作者：
Dawood, Shaheenah;Broglio, Kristine;Giordano, Sharon H.
通讯作者：
Giordano, Sharon H.
影响因子：
6.2
作者：
Cristofanilli, Massimo;Valero, Vicente;Hortobagyi, Gabriel N.
通讯作者：
Hortobagyi, Gabriel N.